Stephen Schexnayder
Concepts (285)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cardiopulmonary Resuscitation | 34 | 2023 | 133 | 5.510 |
Why?
| Heart Arrest | 19 | 2022 | 149 | 3.190 |
Why?
| Emergency Medical Services | 18 | 2022 | 109 | 2.380 |
Why?
| Out-of-Hospital Cardiac Arrest | 11 | 2023 | 26 | 1.700 |
Why?
| American Heart Association | 13 | 2022 | 32 | 1.170 |
Why?
| Pediatrics | 6 | 2022 | 279 | 1.060 |
Why?
| Child | 45 | 2023 | 6847 | 0.970 |
Why?
| Hypnotics and Sedatives | 2 | 2019 | 75 | 0.880 |
Why?
| Brugada Syndrome | 1 | 2021 | 5 | 0.780 |
Why?
| Tachycardia, Ventricular | 1 | 2021 | 44 | 0.750 |
Why?
| Intensive Care Units, Pediatric | 5 | 2022 | 169 | 0.720 |
Why?
| Heart Massage | 3 | 2017 | 7 | 0.720 |
Why?
| Defibrillators, Implantable | 1 | 2021 | 60 | 0.720 |
Why?
| Cardiology | 6 | 2020 | 89 | 0.700 |
Why?
| Deep Sedation | 1 | 2019 | 3 | 0.690 |
Why?
| Adjuvants, Anesthesia | 1 | 2019 | 9 | 0.690 |
Why?
| Spinal Puncture | 1 | 2019 | 16 | 0.680 |
Why?
| Propofol | 1 | 2019 | 21 | 0.680 |
Why?
| Fentanyl | 1 | 2019 | 36 | 0.670 |
Why?
| Advanced Cardiac Life Support | 7 | 2022 | 10 | 0.620 |
Why?
| Adolescent | 21 | 2022 | 6356 | 0.600 |
Why?
| Humans | 67 | 2023 | 49974 | 0.590 |
Why?
| Analgesics, Opioid | 1 | 2022 | 552 | 0.590 |
Why?
| Encephalitis Virus, Eastern Equine | 1 | 2016 | 2 | 0.580 |
Why?
| Encephalomyelitis, Equine | 1 | 2016 | 2 | 0.580 |
Why?
| Consensus | 8 | 2021 | 148 | 0.550 |
Why?
| Substance-Related Disorders | 1 | 2022 | 600 | 0.530 |
Why?
| Health Education | 1 | 2017 | 156 | 0.530 |
Why?
| Critical Illness | 3 | 2022 | 288 | 0.510 |
Why?
| Emergencies | 6 | 2020 | 86 | 0.500 |
Why?
| Child, Preschool | 22 | 2023 | 3871 | 0.490 |
Why?
| Death, Sudden, Cardiac | 3 | 2022 | 53 | 0.480 |
Why?
| Curriculum | 1 | 2017 | 401 | 0.470 |
Why?
| Critical Care | 4 | 2022 | 213 | 0.460 |
Why?
| Emergency Service, Hospital | 4 | 2020 | 486 | 0.440 |
Why?
| Arkansas | 7 | 2019 | 1977 | 0.410 |
Why?
| Practice Guidelines as Topic | 5 | 2020 | 449 | 0.400 |
Why?
| Infant | 19 | 2020 | 3567 | 0.380 |
Why?
| Resuscitation | 3 | 2006 | 73 | 0.370 |
Why?
| Respiration, Artificial | 4 | 2019 | 274 | 0.360 |
Why?
| United States | 18 | 2022 | 4860 | 0.310 |
Why?
| Infant, Newborn | 13 | 2022 | 2772 | 0.300 |
Why?
| Internship and Residency | 2 | 2004 | 443 | 0.300 |
Why?
| Emergency Medicine | 2 | 2017 | 52 | 0.290 |
Why?
| Parental Consent | 1 | 2006 | 12 | 0.280 |
Why?
| Male | 23 | 2022 | 25241 | 0.280 |
Why?
| Embolism, Fat | 1 | 2006 | 2 | 0.280 |
Why?
| Cardiovascular Diseases | 3 | 2020 | 440 | 0.270 |
Why?
| Intubation, Intratracheal | 2 | 2019 | 118 | 0.250 |
Why?
| Spinal Fusion | 1 | 2006 | 70 | 0.250 |
Why?
| Patient Selection | 1 | 2006 | 253 | 0.250 |
Why?
| Monitoring, Physiologic | 3 | 2016 | 120 | 0.250 |
Why?
| Attitude to Health | 1 | 2006 | 192 | 0.250 |
Why?
| Defibrillators | 2 | 2017 | 7 | 0.240 |
Why?
| Gas Gangrene | 1 | 2004 | 1 | 0.240 |
Why?
| Neuromuscular Blocking Agents | 1 | 2004 | 7 | 0.240 |
Why?
| Quality Control | 1 | 2004 | 94 | 0.240 |
Why?
| Retrospective Studies | 12 | 2023 | 6108 | 0.240 |
Why?
| Accreditation | 1 | 2004 | 60 | 0.240 |
Why?
| Neuromuscular Blockade | 1 | 2004 | 11 | 0.240 |
Why?
| Scoliosis | 2 | 2019 | 59 | 0.230 |
Why?
| Emergency Treatment | 2 | 2020 | 29 | 0.220 |
Why?
| Reye Syndrome | 1 | 2003 | 3 | 0.220 |
Why?
| Constipation | 1 | 2022 | 35 | 0.210 |
Why?
| Polyethylene Glycols | 1 | 2022 | 93 | 0.210 |
Why?
| Shock, Septic | 2 | 2020 | 78 | 0.200 |
Why?
| Adult | 11 | 2022 | 13236 | 0.200 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 121 | 0.200 |
Why?
| Aspirin | 1 | 2003 | 114 | 0.200 |
Why?
| Substance Abuse Detection | 1 | 2022 | 92 | 0.200 |
Why?
| Psychotropic Drugs | 1 | 2022 | 77 | 0.190 |
Why?
| Attitude of Health Personnel | 1 | 2004 | 347 | 0.190 |
Why?
| Cardiology Service, Hospital | 1 | 2020 | 15 | 0.190 |
Why?
| Teaching | 1 | 2002 | 116 | 0.190 |
Why?
| Life Support Care | 1 | 2020 | 17 | 0.190 |
Why?
| Health Information Systems | 1 | 2021 | 20 | 0.190 |
Why?
| Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 23 | 0.180 |
Why?
| Pericardial Effusion | 1 | 2021 | 43 | 0.180 |
Why?
| Evidence-Based Medicine | 2 | 2020 | 247 | 0.180 |
Why?
| Bites and Stings | 1 | 2000 | 22 | 0.180 |
Why?
| Electric Countershock | 2 | 2017 | 30 | 0.180 |
Why?
| Seizures | 2 | 2021 | 195 | 0.180 |
Why?
| Fatal Outcome | 3 | 2006 | 195 | 0.170 |
Why?
| Female | 19 | 2021 | 26472 | 0.170 |
Why?
| Patient Transfer | 2 | 2010 | 94 | 0.170 |
Why?
| Fellowships and Scholarships | 1 | 2000 | 111 | 0.170 |
Why?
| Hypothermia, Induced | 1 | 2019 | 39 | 0.170 |
Why?
| Electrocardiography | 1 | 2021 | 257 | 0.170 |
Why?
| School Health Services | 1 | 2019 | 49 | 0.170 |
Why?
| Hospital Mortality | 3 | 2016 | 409 | 0.160 |
Why?
| Educational Measurement | 1 | 2000 | 208 | 0.160 |
Why?
| Age Factors | 6 | 2020 | 1087 | 0.160 |
Why?
| Inpatients | 2 | 2011 | 190 | 0.160 |
Why?
| Patient Care Team | 1 | 2000 | 254 | 0.160 |
Why?
| Education, Medical, Graduate | 1 | 2000 | 205 | 0.160 |
Why?
| Rabies | 1 | 2018 | 5 | 0.160 |
Why?
| Cholinesterase Reactivators | 1 | 1998 | 1 | 0.160 |
Why?
| Pralidoxime Compounds | 1 | 1998 | 1 | 0.160 |
Why?
| Evidence-Based Emergency Medicine | 1 | 2017 | 2 | 0.150 |
Why?
| Insecticides | 1 | 1998 | 15 | 0.150 |
Why?
| Organophosphorus Compounds | 1 | 1998 | 15 | 0.150 |
Why?
| Antidotes | 1 | 1998 | 29 | 0.150 |
Why?
| Immunoglobulins, Intravenous | 1 | 2018 | 54 | 0.150 |
Why?
| Quality Indicators, Health Care | 1 | 2017 | 86 | 0.140 |
Why?
| Physicians' Offices | 1 | 1996 | 5 | 0.140 |
Why?
| Serologic Tests | 1 | 2016 | 26 | 0.140 |
Why?
| Equipment and Supplies | 1 | 1996 | 17 | 0.140 |
Why?
| Antibodies, Viral | 1 | 2016 | 88 | 0.140 |
Why?
| Citrulline | 1 | 2017 | 95 | 0.140 |
Why?
| Mass Screening | 1 | 2019 | 353 | 0.140 |
Why?
| Tomography, X-Ray Computed | 3 | 2016 | 1159 | 0.140 |
Why?
| Databases, Factual | 1 | 2019 | 658 | 0.140 |
Why?
| Asphyxia | 1 | 2015 | 9 | 0.130 |
Why?
| Arginine | 1 | 2017 | 179 | 0.130 |
Why?
| Prospective Studies | 5 | 2023 | 2364 | 0.120 |
Why?
| Extracorporeal Membrane Oxygenation | 3 | 2015 | 287 | 0.120 |
Why?
| Registries | 5 | 2019 | 522 | 0.120 |
Why?
| Cardiac Surgical Procedures | 2 | 2014 | 297 | 0.120 |
Why?
| Dietary Proteins | 1 | 2017 | 242 | 0.120 |
Why?
| Heart Diseases | 2 | 2016 | 206 | 0.110 |
Why?
| Anti-Bacterial Agents | 2 | 2016 | 744 | 0.110 |
Why?
| Educational Status | 2 | 2023 | 222 | 0.100 |
Why?
| Algorithms | 1 | 2015 | 615 | 0.100 |
Why?
| Asphyxia Neonatorum | 1 | 2010 | 10 | 0.090 |
Why?
| Risk Factors | 5 | 2021 | 3613 | 0.090 |
Why?
| Wounds and Injuries | 1 | 2012 | 276 | 0.080 |
Why?
| Respiratory Insufficiency | 1 | 2010 | 113 | 0.080 |
Why?
| Education, Medical | 1 | 2011 | 112 | 0.080 |
Why?
| Acute Kidney Injury | 1 | 2012 | 284 | 0.080 |
Why?
| Vasopressins | 1 | 2009 | 39 | 0.080 |
Why?
| Atropine | 2 | 2020 | 30 | 0.080 |
Why?
| Prognosis | 4 | 2016 | 1942 | 0.080 |
Why?
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2008 | 19 | 0.080 |
Why?
| Heart Defects, Congenital | 1 | 2014 | 595 | 0.080 |
Why?
| North America | 1 | 2008 | 64 | 0.080 |
Why?
| Anti-Arrhythmia Agents | 2 | 2018 | 79 | 0.080 |
Why?
| Respiratory Tract Infections | 2 | 2003 | 75 | 0.080 |
Why?
| Treatment Outcome | 4 | 2020 | 5141 | 0.080 |
Why?
| Proton Pump Inhibitors | 1 | 2008 | 84 | 0.080 |
Why?
| Decision Making | 1 | 2010 | 265 | 0.070 |
Why?
| Blood-Borne Pathogens | 1 | 2007 | 7 | 0.070 |
Why?
| Equipment Contamination | 1 | 2007 | 18 | 0.070 |
Why?
| Comorbidity | 2 | 2021 | 615 | 0.070 |
Why?
| Catheterization | 1 | 2007 | 96 | 0.070 |
Why?
| Survival Rate | 3 | 2016 | 894 | 0.070 |
Why?
| Cross Infection | 1 | 2007 | 95 | 0.070 |
Why?
| Young Adult | 4 | 2019 | 3958 | 0.070 |
Why?
| Time Factors | 3 | 2010 | 2903 | 0.070 |
Why?
| Animals | 2 | 2016 | 13187 | 0.060 |
Why?
| Carbon Dioxide | 2 | 2016 | 91 | 0.060 |
Why?
| Middle Aged | 5 | 2019 | 12069 | 0.060 |
Why?
| Clostridium | 1 | 2004 | 15 | 0.060 |
Why?
| Laryngeal Masks | 1 | 2004 | 7 | 0.060 |
Why?
| Research Design | 1 | 2006 | 344 | 0.060 |
Why?
| Prevalence | 2 | 2019 | 944 | 0.060 |
Why?
| Posture | 1 | 2004 | 59 | 0.060 |
Why?
| Leg | 1 | 2004 | 122 | 0.060 |
Why?
| Masks | 1 | 2004 | 30 | 0.060 |
Why?
| Airway Obstruction | 1 | 2004 | 47 | 0.060 |
Why?
| Positive-Pressure Respiration | 1 | 2004 | 57 | 0.060 |
Why?
| Cardiac Catheterization | 2 | 2019 | 201 | 0.060 |
Why?
| Parents | 1 | 2006 | 314 | 0.060 |
Why?
| Infusions, Intravenous | 2 | 2008 | 206 | 0.060 |
Why?
| Radiography | 1 | 2004 | 489 | 0.050 |
Why?
| Motorcycles | 1 | 2002 | 10 | 0.050 |
Why?
| Head Protective Devices | 1 | 2002 | 18 | 0.050 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2004 | 185 | 0.050 |
Why?
| Cohort Studies | 2 | 2021 | 1422 | 0.050 |
Why?
| Accidents, Traffic | 1 | 2002 | 88 | 0.050 |
Why?
| Fever | 1 | 2003 | 114 | 0.050 |
Why?
| Craniocerebral Trauma | 1 | 2002 | 67 | 0.050 |
Why?
| Intensive Care Units | 2 | 2017 | 222 | 0.050 |
Why?
| Forms and Records Control | 1 | 2001 | 11 | 0.050 |
Why?
| Fraud | 1 | 2001 | 4 | 0.050 |
Why?
| Diagnosis, Differential | 2 | 2003 | 1037 | 0.050 |
Why?
| Reference Standards | 1 | 2001 | 56 | 0.050 |
Why?
| Oxygen | 1 | 2004 | 326 | 0.050 |
Why?
| Emergency Medical Service Communication Systems | 1 | 2020 | 2 | 0.050 |
Why?
| Terminology as Topic | 1 | 2001 | 62 | 0.050 |
Why?
| Black Widow Spider | 1 | 2000 | 2 | 0.050 |
Why?
| Scorpions | 1 | 2000 | 2 | 0.050 |
Why?
| Elapidae | 1 | 2000 | 2 | 0.050 |
Why?
| Elapid Venoms | 1 | 2000 | 3 | 0.050 |
Why?
| Hymenoptera | 1 | 2000 | 3 | 0.050 |
Why?
| Insect Bites and Stings | 1 | 2000 | 9 | 0.050 |
Why?
| Spiders | 1 | 2000 | 9 | 0.050 |
Why?
| Viperidae | 1 | 2000 | 5 | 0.050 |
Why?
| Crotalid Venoms | 1 | 2000 | 9 | 0.050 |
Why?
| Antivenins | 1 | 2000 | 11 | 0.050 |
Why?
| Snake Bites | 1 | 2000 | 16 | 0.050 |
Why?
| Extracorporeal Circulation | 1 | 2019 | 9 | 0.040 |
Why?
| New Orleans | 1 | 2019 | 5 | 0.040 |
Why?
| Adrenal Cortex Hormones | 1 | 2020 | 94 | 0.040 |
Why?
| Arrhythmias, Cardiac | 1 | 2020 | 95 | 0.040 |
Why?
| Survivors | 1 | 2021 | 126 | 0.040 |
Why?
| Vulnerable Populations | 1 | 2019 | 45 | 0.040 |
Why?
| Societies, Medical | 1 | 2000 | 175 | 0.040 |
Why?
| Adjuvants, Immunologic | 1 | 1999 | 51 | 0.040 |
Why?
| Epinephrine | 1 | 2019 | 96 | 0.040 |
Why?
| Health Care Surveys | 1 | 2019 | 173 | 0.040 |
Why?
| Consensus Development Conferences as Topic | 1 | 2018 | 12 | 0.040 |
Why?
| Amiodarone | 1 | 2018 | 22 | 0.040 |
Why?
| Vasoconstrictor Agents | 1 | 2019 | 84 | 0.040 |
Why?
| Magnesium | 1 | 2018 | 35 | 0.040 |
Why?
| Patient Readmission | 1 | 2021 | 219 | 0.040 |
Why?
| Health Personnel | 1 | 2021 | 246 | 0.040 |
Why?
| Lidocaine | 1 | 2018 | 49 | 0.040 |
Why?
| Hyperthermia, Induced | 1 | 2019 | 117 | 0.040 |
Why?
| Advisory Committees | 1 | 2018 | 63 | 0.040 |
Why?
| Lyssavirus | 1 | 2018 | 1 | 0.040 |
Why?
| Rabies virus | 1 | 2018 | 4 | 0.040 |
Why?
| Rabies Vaccines | 1 | 2018 | 4 | 0.040 |
Why?
| Cholinesterases | 1 | 1998 | 2 | 0.040 |
Why?
| Follow-Up Studies | 2 | 2014 | 2182 | 0.040 |
Why?
| Immunization, Passive | 1 | 2018 | 29 | 0.040 |
Why?
| False Positive Reactions | 1 | 2018 | 63 | 0.040 |
Why?
| Carbamates | 1 | 1998 | 16 | 0.040 |
Why?
| Poisoning | 1 | 1998 | 25 | 0.040 |
Why?
| Hypernatremia | 1 | 1997 | 3 | 0.040 |
Why?
| Half-Life | 1 | 1998 | 84 | 0.040 |
Why?
| Munchausen Syndrome by Proxy | 1 | 1997 | 2 | 0.040 |
Why?
| Dehydration | 1 | 1997 | 21 | 0.040 |
Why?
| Tissue Distribution | 1 | 1998 | 163 | 0.040 |
Why?
| Anti-Anxiety Agents | 1 | 1997 | 35 | 0.040 |
Why?
| Referral and Consultation | 1 | 2019 | 285 | 0.040 |
Why?
| Length of Stay | 1 | 2021 | 619 | 0.040 |
Why?
| Brain Edema | 1 | 1997 | 41 | 0.040 |
Why?
| Parent-Child Relations | 1 | 1997 | 72 | 0.040 |
Why?
| Carbon Isotopes | 1 | 2017 | 68 | 0.040 |
Why?
| Tyrosine | 1 | 2017 | 95 | 0.040 |
Why?
| Cerebral Hemorrhage | 1 | 1997 | 104 | 0.030 |
Why?
| Incidence | 2 | 2014 | 1003 | 0.030 |
Why?
| Circadian Rhythm | 1 | 2017 | 88 | 0.030 |
Why?
| Cytokines | 1 | 1999 | 612 | 0.030 |
Why?
| Phenylalanine | 1 | 2017 | 128 | 0.030 |
Why?
| Leucine | 1 | 2017 | 116 | 0.030 |
Why?
| Emergency Responders | 1 | 2015 | 4 | 0.030 |
Why?
| Ventricular Fibrillation | 1 | 2015 | 16 | 0.030 |
Why?
| Early Medical Intervention | 1 | 2015 | 8 | 0.030 |
Why?
| Enteral Nutrition | 1 | 2017 | 147 | 0.030 |
Why?
| Isotonic Solutions | 1 | 2015 | 18 | 0.030 |
Why?
| Propensity Score | 1 | 2016 | 123 | 0.030 |
Why?
| Cardiovascular Agents | 1 | 2015 | 54 | 0.030 |
Why?
| Aged | 2 | 2019 | 9310 | 0.030 |
Why?
| Recurrence | 1 | 2016 | 652 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 1998 | 1376 | 0.030 |
Why?
| Postoperative Period | 1 | 2014 | 170 | 0.030 |
Why?
| Pulmonary Atelectasis | 1 | 1993 | 10 | 0.030 |
Why?
| Logistic Models | 1 | 2016 | 888 | 0.030 |
Why?
| Bronchoscopy | 1 | 1993 | 71 | 0.030 |
Why?
| Lung Diseases | 1 | 1993 | 92 | 0.030 |
Why?
| Blood Pressure Monitors | 1 | 2010 | 10 | 0.020 |
Why?
| Blood Pressure Determination | 1 | 2010 | 40 | 0.020 |
Why?
| Single-Blind Method | 1 | 2010 | 116 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2011 | 577 | 0.020 |
Why?
| Disease Progression | 1 | 2012 | 825 | 0.020 |
Why?
| Education, Medical, Continuing | 1 | 2009 | 68 | 0.020 |
Why?
| Program Evaluation | 1 | 2010 | 354 | 0.020 |
Why?
| Hospitals, Pediatric | 1 | 2009 | 239 | 0.020 |
Why?
| Arizona | 1 | 2007 | 12 | 0.020 |
Why?
| Disinfectants | 1 | 2007 | 12 | 0.020 |
Why?
| Administration, Oral | 1 | 2008 | 426 | 0.020 |
Why?
| Chlorhexidine | 1 | 2007 | 11 | 0.020 |
Why?
| Echocardiography | 1 | 2010 | 378 | 0.020 |
Why?
| Legislation as Topic | 1 | 2002 | 9 | 0.010 |
Why?
| Sex Distribution | 1 | 2002 | 134 | 0.010 |
Why?
| Age Distribution | 1 | 2002 | 168 | 0.010 |
Why?
| Probability | 1 | 2002 | 164 | 0.010 |
Why?
| Statistics, Nonparametric | 1 | 2002 | 194 | 0.010 |
Why?
| Injury Severity Score | 1 | 2002 | 159 | 0.010 |
Why?
| Analysis of Variance | 1 | 2002 | 562 | 0.010 |
Why?
| Survival Analysis | 1 | 2002 | 653 | 0.010 |
Why?
| Temazepam | 1 | 1997 | 1 | 0.010 |
Why?
| Echoencephalography | 1 | 1997 | 10 | 0.010 |
Why?
| Lorazepam | 1 | 1997 | 11 | 0.010 |
Why?
| Nuclear Family | 1 | 1997 | 15 | 0.010 |
Why?
| Apnea | 1 | 1997 | 18 | 0.010 |
Why?
| Autopsy | 1 | 1997 | 46 | 0.010 |
Why?
| Hospitals, University | 1 | 1997 | 77 | 0.010 |
Why?
| Patient Admission | 1 | 1997 | 77 | 0.010 |
Why?
| Feces | 1 | 1997 | 134 | 0.010 |
Why?
| Brain Injuries | 1 | 1997 | 160 | 0.010 |
Why?
| Child Abuse | 1 | 1997 | 136 | 0.010 |
Why?
| Fiber Optic Technology | 1 | 1993 | 16 | 0.010 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 1993 | 39 | 0.010 |
Why?
|
|
Schexnayder's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|